Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?
Search

Commentary and Opinion by R. Lewis Dark

Revenue Concerns to Watch at Home and Abroad

Commentary and Opinion by R. Lewis Dark /

This issue of The Dark Report explores long-term revenue interests from two angles, both of which are important for clinical laboratory leaders and pathology practice owners to contemplate. One of our briefings delves into how a lab fought back against payers that were denying claims for mysterious reasons. It is not the first organization to […]

To access this post, you must purchase The Dark Report.

Revenue Concerns to Watch at Home and Abroad Read More »

Permanent PAMA Reform Must Happen in 2026

Commentary and Opinion by R. Lewis Dark /

Previously, it would have been hard to imagine even in the current political landscape that US immigration policy would somehow intersect with clinical laboratory test reimbursement. Yet, in recent weeks, that exact scenario happened as lawmakers reacted to a fatal shooting of a citizen protester by a federal agent in Minneapolis, during a crackdown on

To access this post, you must purchase The Dark Report.

Permanent PAMA Reform Must Happen in 2026 Read More »

Crucial Themes Shape 2026 Executive War College

Commentary and Opinion by R. Lewis Dark /

With 2026 now upon us, our attention here at The Dark Report starts to look towards April and the 31st Annual Executive War College on Diagnostics, Clinical Laboratory, and Pathology Management. The conference’s organizers and external advisors are hard at work shaping an agenda that brings together the most relevant macro trends, technological advancements, and

To access this post, you must purchase The Dark Report.

Crucial Themes Shape 2026 Executive War College Read More »

In 2026, Challenges Can Be Business Opportunities

Commentary and Opinion by R. Lewis Dark /

Looking over The Dark Report’s annual rundown of the most significant clinical laboratory and pathology stories of the past year, the world “tumult” comes to mind. At points during the past year the tumult leaned in the favor of labs, such as a federal judge vacating the Food and Drug Administration’s rule on laboratory developed

To access this post, you must purchase The Dark Report.

In 2026, Challenges Can Be Business Opportunities Read More »

Paper, the Cloud, and Lessons for Laboratories

Commentary and Opinion by R. Lewis Dark /

Paper requisitions. Cloud-based data. These two concepts are on opposite ends of the spectrum in clinical labs and pathology practices. Paper is an old-school institution that some labs continue to use. How many draw stations still require patients to fill out a hardcopy form and then immediately place it in a basket for a phlebotomist

To access this post, you must purchase The Dark Report.

Paper, the Cloud, and Lessons for Laboratories Read More »

Congress is Listening. Labs Must Step Up on PAMA

Commentary and Opinion by R. Lewis Dark /

Just as The Dark Report went to press for this issue, the US federal government reopened after the longest shutdown in the country’s history. And while political pundits on both sides of the spectrum argued about who won and lost during the shutdown, it was clear that the clinical laboratory industry quietly notched a significant

To access this post, you must purchase The Dark Report.

Congress is Listening. Labs Must Step Up on PAMA Read More »

More Signs of Shifting Sands in the Lab World

Commentary and Opinion by R. Lewis Dark /

If you feel like the ground is shifting under your feet in the clinical laboratory world, I would agree with you. It’s clear that situations are changing in the diagnostics market. This issue of The Dark Report is stocked with evidence of our observation. Take, for example, the lead briefing, which digs into the College

To access this post, you must purchase The Dark Report.

More Signs of Shifting Sands in the Lab World Read More »

Observing a Champion … and Some Antagonists

Commentary and Opinion by R. Lewis Dark /

Judging from the briefings we present in this issue, a “cheers and jeers” column seems an appropriate use of my soapbox. First, the well-earned cheers. An in-depth case study traces how Kootenai Health, which had seen its clinical laboratory outreach business outsourced to a national lab, took a series of strategic steps to win back

To access this post, you must purchase The Dark Report.

Observing a Champion … and Some Antagonists Read More »

RESULTS Act Offers Another Chance at PAMA Relief

Commentary and Opinion by R. Lewis Dark /

OVER YOUR SHOULDER, YOU MAY HEAR THE CLOCK TICKING when it comes to laboratory test reimbursement rate cuts coming under the Protecting Access to Medicare Act of 2014 (PAMA). Short of action by Congress, on Jan. 1, 2026, more than 800 tests will get hit with up to a 15% reduction in rates. It’s a

To access this post, you must purchase The Dark Report.

RESULTS Act Offers Another Chance at PAMA Relief Read More »

An Insider’s Observances of Lab Outreach Deals

Commentary and Opinion by R. Lewis Dark /

THERE ARE MANY WAYS TO VIEW CLINICAL LABORATORY OUTREACH ACQUISITIONS and the enormous amount of money changing hands in these deals. From one point of view, those fearful of the continued expansion of national lab giants like Labcorp and Quest Diagnostics may shiver every time one of these companies grabs a new outreach site. Meanwhile,

To access this post, you must purchase The Dark Report.

An Insider’s Observances of Lab Outreach Deals Read More »

;